885618-31-5

Basic information

• Product Name: 2-CHLORO-4-MORPHOLINOTHIENO[3,2-D]PYRIMIDINE-6-CARBALDEHYDE
• Synonyms: 2-CHLORO-4-MORPHOLINOTHIENO[3,2-D]PYRIMIDINE-6-CARBALDEHYDE;2-chloro-4-(Morpholin-4-yl)thieno[3,2-d]pyriMidine-6-carbaldehyde;Thieno[3,2-d]pyriMidine-6-carboxaldehyde, 2-chloro-4-(4-Morpholinyl)-;2-Chloro-4-(Morpholin-4-yl)thieno[3,2-d]pyriMidine-6-carboxaldehyde;2-CHLORO-4-MORPHOLINOTHIENO[3,2-D]PYRIMIDINE-6-CARBALDEHYDE-5;2-chloro-4-(4-morpholinyl)-Thieno[3,2-d]pyrimidine-6-carboxaldehyde
• CAS NO: 885618-31-5
• Molecular Formula: C₁₁H₁₀ClN₃O₂S
• Molecular Weight: 283.74
• Product Categories: Heterocycle-Pyrimidine series
• Mol File: 885618-31-5.mol
• Article Data: 35

Chemical Properties

• Appearance: /
• Density: 1.522g/cm³
• Refractive Index: 1.7
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 2-CHLORO-4-MORPHOLINOTHIENO[3,2-D]PYRIMIDINE-6-CARBALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-CHLORO-4-MORPHOLINOTHIENO[3,2-D]PYRIMIDINE-6-CARBALDEHYDE(885618-31-5)
• EPA Substance Registry System: 2-CHLORO-4-MORPHOLINOTHIENO[3,2-D]PYRIMIDINE-6-CARBALDEHYDE(885618-31-5)

Safety Data

• Hazardous Substances Data: 885618-31-5(Hazardous Substances Data)

Usage

General Description

2-CHLORO-4-MORPHOLINOTHIENO[3,2-D]PYRIMIDINE-6-CARBALDEHYDE is a chemical compound with a chloro group and a morpholino group attached to a thiophene-pyrimidine ring system. It also contains a carb aldehyde functional group, which makes it a versatile building block for the synthesis of various organic compounds. This chemical may have potential applications in medicinal chemistry, agrochemicals, and material science due to its unique structure and reactivity. Its precise properties and potential uses would need to be determined through further research and testing.

InChI:InChI=1/C11H10ClN3O2S/c12-11-13-8-5-7(6-16)18-9(8)10(14-11)15-1-3-17-4-2-15/h5-6H,1-4H2

Upstream product

• 16233-51-5 2,4-dihydroxythieno[3,2-d]pyrimidine 
• 98-79-3 L-Pyroglutamic acid 
• 113400-36-5 (S)-2-benzyl 1-tert-butyl 5-oxopyrrolidine-1,2-dicarboxylate 
• 22288-78-4 Methyl 3-aminothiophene-2-carboxylate 
• 16233-51-5 1H-thieno[3,2-d]pyrimidine-2,4-dione 
• 16234-14-3 2,4-dichlorothieno[3,2-d]pyrimidine 
• 16234-15-4 2-chloro-4-morpholinothieno[3,2-d]pyrimidine 
• 68-12-2 N,N-dimethyl-formamide 

Downstream Products

• 885675-66-1 4-(2-chloro-6-((4-(methylsulfonyl)piperazin-1-yl)methyl)thieno[3,2-d]-pyrimidin-4-yl)morpholine 
• 885675-75-2 C₁₇H₂₄ClN₅O₂S 
• 955979-15-4 1-(2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6-yl)-N-methylmethanamine 
• 885617-10-7 tert-butyl 4-((2-(3-hydroxyphenyl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazine-1-carboxylate 
• 885698-98-6 4-(6-(bromomethyl)-2-chlorothieno[3,2-d]pyrimidin-4-yl)morpholine 
• 1235450-27-7 Ethyl 2-((2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methylamino)pyrimidine-5-carboxylate 
• 1235450-94-8 methyl 2-(((2-(4-(aminomethyl)phenyl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)(methyl)amino)pyrimidine-5-carboxylate 
• 1235450-97-1 methyl 2-(((2-(3-(aminomethyl)phenyl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)(methyl)amino)pyrimidine-5-carboxylate 
• 1235451-07-6 ethyl 2-(((2-(4-aminophenyl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)(methyl)amino)pyrimidine-5-carboxylate 
• 1235450-95-9 ethyl 2-(((2-(4-(acetamidomethyl)phenyl)-4-morpholinothieno[3,2-d]pyrimidine-6-yl)Methyl)(methyl)amino)pyrimidine-5-carboxylate 
• 1235450-96-0 2-(((2-(4-(aminomethyl)phenyl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)(methyl)amino)pyrimidine-5-carboxylic acid 
• 1235450-98-2 ethyl 2-(((2-(3-(acetamidomethyl)phenyl)-4-morpholinothieno[3,2-d]pyrimidine-6-yl)Methyl)(methyl)amino)pyrimidine-5-carboxylate 
• 1235450-99-3 2-(((2-(3-(aminomethyl)phenyl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)(methyl)amino)pyrimidine-5-carboxylic acid 
• 1235451-08-7 ethyl 2-(((2-(4-acetamidophenyl)-4-morpholinothieno-[3,2-d]pyrimidin-6-yl)methyl)(methyl)amino)pyrimidine-5-carboxylate 

Relevant articles and documents

PARP-1/PI3K double-target inhibitor or pharmaceutically acceptable salt thereof, preparation method and application thereof

The invention discloses a PARP-1/PI3K double-target inhibitor or a pharmaceutically acceptable salt thereof, a preparation method and application thereof. According to the invention, the single active component can play a dual inhibition role on PARP-1 and PI3K, so that the dosage is reduced, the treatment effect is improved, and the toxic and side effects are reduced; and the dual inhibition effect on PARP-1 and PI3K is significant, the IC50 value of each target does not exceed 1.0 [mu]M, and the drug using the PARP-1/PI3K double-target inhibitor as the active component can be used for treating a variety of cancers or tumors related to PARP-1 and/or PI3K.

COMBINATION THERAPY WITH A PHOSPHOINOSITIDE 3-KINASE INHIBITOR WITH A ZINC BINDING MOIETY

The invention provides a method of treating cancer in a subject in need thereof, comprising administering to the subject: (a) a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein R is hydrogen or an acyl group; and (b) a PD-1 signaling inhibitor; wherein the compound of Formula I or pharmaceutically acceptable salt thereof and the PD-1 signaling inhibitor are administered in amounts which in combination are therapeutically effective. The invention further provides a pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, a PD-1 signaling inhibitor and a pharmaceutically acceptable carrier or excipient.

Preparation method of thienopyrimidine compounds and application thereof

The invention relates to thienopyrimidine derivatives as shown in a general formula I, pharmaceutically acceptable salts or prodrugs and a preparation method thereof, which belong to the technical field of medicinal chemistry. In the general formula I, substituent groups L and R2 have meanings given in the specification. The invention also relates to a compound shown in the general formula I, which has a strong effect of inhibiting PI3K. The invention also relates to an application of the compounds and pharmaceutically acceptable salts, solvates or prodrugs thereof in preparation of drugs fortreating and/or preventing diseases caused by abnormal high expression of PI3K, especially the application in preparation of drugs for treating and/or preventing cancers.